ValuEngine Lowers BioXcel Therapeutics (NASDAQ:BTAI) to Hold

ValuEngine cut shares of BioXcel Therapeutics (NASDAQ:BTAI) from a buy rating to a hold rating in a research note published on Monday, ValuEngine reports.

A number of other research analysts have also commented on the stock. HC Wainwright restated a buy rating on shares of Zomedica Pharmaceuticals in a research note on Wednesday, June 5th. Zacks Investment Research upgraded shares of GCP Applied Technologies from a sell rating to a hold rating in a research note on Friday, May 31st.

NASDAQ BTAI traded down $0.07 during trading on Monday, reaching $10.87. The company’s stock had a trading volume of 11,300 shares, compared to its average volume of 72,072. The company has a current ratio of 5.59, a quick ratio of 5.59 and a debt-to-equity ratio of 0.04. The firm has a market capitalization of $170.60 million, a price-to-earnings ratio of -8.20 and a beta of 3.04. BioXcel Therapeutics has a twelve month low of $2.41 and a twelve month high of $12.16. The business’s fifty day moving average is $10.89.

BioXcel Therapeutics (NASDAQ:BTAI) last posted its quarterly earnings data on Tuesday, May 7th. The company reported ($0.46) EPS for the quarter, beating analysts’ consensus estimates of ($0.48) by $0.02. On average, equities analysts predict that BioXcel Therapeutics will post -2.19 earnings per share for the current fiscal year.

An institutional investor recently bought a new position in BioXcel Therapeutics stock. Creative Planning purchased a new position in shares of BioXcel Therapeutics Inc (NASDAQ:BTAI) during the first quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The fund purchased 30,550 shares of the company’s stock, valued at approximately $302,000. Creative Planning owned 0.20% of BioXcel Therapeutics as of its most recent SEC filing. Hedge funds and other institutional investors own 16.05% of the company’s stock.

BioXcel Therapeutics Company Profile

BioXcel Therapeutics, Inc, a clinical stage biopharmaceutical company, focuses on novel artificial intelligence-based drug development in the fields of neuroscience and immuno-oncology in the United States. The company is involved in developing BXCL501, a sublingual thin film formulation of dexmedetomidine designed for acute treatment of agitation resulting from neurological and psychiatric disorders; and BXCL701, an immuno-oncology agent designed for the treatment of prostate and pancreatic cancers.

Further Reading: Trading Options- What is a Strangle?

To view ValuEngine’s full report, visit ValuEngine’s official website.

Receive News & Ratings for BioXcel Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for BioXcel Therapeutics and related companies with's FREE daily email newsletter.